Zydus settles Astellas patent suit, to pay USD 120M plus licensing fees

Regulatory & Legal View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.3%Reaction day

₹899.00

prior close

₹900.30

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.5%+2.8% vs market

Pharmaceuticals peers, median of 157sector-0.7%+2.9% vs sector

On the reaction day the stock moved 2.8 pts more than Nifty 100 and 2.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.3

15m

+0.2

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.3-0.5+2.8-0.7+2.9

Next day

+0.8-1.9+2.7-1.4+2.3

+1.2-1.0+2.3-2.1+3.4

+0.8-0.8+1.6-1.6+2.4

+1.5-0.4+1.9-1.6+3.1

+0.3-1.9+2.1-2.5+2.7

+0.7-0.9+1.6-2.9+3.6

15d

+1.3-5.5+6.8-6.5+7.8

+1.9-8.3+10.2-6.6+8.5

+2.4-7.5+9.9-3.5+5.9

+3.3-8.6+11.9+0.7+2.6

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus and its US subsidiary have entered a settlement agreement with Astellas Pharma to end patent litigation over the generic drug Mirabegron (brand Myrbetriq). Zydus will pay Astellas USD 120 million in aggregate, plus a prepaid per-unit licensing fee on US Mirabegron sales until September 2027. The settlement concludes all related litigations and allows Zydus to continue marketing its generic Mirabegron in the US.

Likely market impact

Litigation overhang removed but USD 120M payout plus ongoing royalties may dent margins while Zydus retains the US generic market.